Posted by Michael Wonder on 17 Mar 2017
Shire receives European approval for label extension of Cinryze to prevent and treat hereditary angioedema (HAE) attacks in paediatric patients with HAE
16 March 2017 - Cinryze is now the first and only hereditary angioedema treatment approved for routine prevention in paediatrics.
Shire announced that the European Commission (EC) has approved a label extension granting three new indications for Cinryze (C1 inhibitor [human]), broadening its use to children with Hereditary angiodema (HAE), a rare, genetic disorder that results in recurring attacks of edema (swelling).
Cinryze is now indicated for routine prevention of angioedema attacks in children (ages 6 years and above) with severe and recurrent attacks of HAE who are intolerant to or insufficiently protected by oral preventions treatments, or patients who are inadequately managed with repeated acute treatment.2 It is the first and only HAE treatment with this indication in paediatric patients.
Cinryze is also now approved for the treatment and pre-procedure prevention of angioedema attacks in children (ages 2 years and above) with HAE.
